Stock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum

Stock Track

26 Feb

Tarsus Pharmaceuticals, Inc. (TARS) stock surged 5.74% in the pre-market session on Wednesday, driven by the company's impressive 2024 financial results and robust growth prospects for its leading product XDEMVY.

The biopharmaceutical company reported stellar full-year 2024 net product sales of $180.1 million for XDEMVY, exceeding expectations and reflecting the successful execution of its commercial strategies. Key highlights included:

- Expansion of the sales force from 100 to 150 representatives, increasing reach to over 15,000 eye care physicians. - Securing commercial and Medicare coverage for XDEMVY, extending to more than 90% of potential patient lives. - Compelling data demonstrating XDEMVY's objective benefits in improving measures of Demodex blepharitis (DB) and patient outcomes like fluctuating vision. - Successful launch of a direct-to-consumer advertising campaign, driving patient engagement and awareness.

Tarsus also provided promising updates on its pipeline, including plans to initiate a Phase 2 trial for its ocular rosacea treatment TP-04 in the second half of 2025 and a Phase 2 study for its Lyme disease prevention program TP-05 in 2026.

Analysts widely applauded Tarsus' strong performance, reiterating Buy ratings and raising price targets, citing the company's impressive growth trajectory, potential for further market penetration, and robust pipeline opportunities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1172093281"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172093281\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1172093281?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172093281","market":"hk","top_or_hot":-1,"title":"Stock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum","media":"Stock Track","content":"<p>Tarsus Pharmaceuticals, Inc. (TARS) stock surged 5.74% in the pre-market session on Wednesday, driven by the company's impressive 2024 financial results and robust growth prospects for its leading product XDEMVY.</p>\n\n<p>The biopharmaceutical company reported stellar full-year 2024 net product sales of $180.1 million for XDEMVY, exceeding expectations and reflecting the successful execution of its commercial strategies. Key highlights included:</p>\n- Expansion of the sales force from 100 to 150 representatives, increasing reach to over 15,000 eye care physicians.\n- Securing commercial and Medicare coverage for XDEMVY, extending to more than 90% of potential patient lives.\n- Compelling data demonstrating XDEMVY's objective benefits in improving measures of Demodex blepharitis (DB) and patient outcomes like fluctuating vision.\n- Successful launch of a direct-to-consumer advertising campaign, driving patient engagement and awareness.\n\n<p>Tarsus also provided promising updates on its pipeline, including plans to initiate a Phase 2 trial for its ocular rosacea treatment TP-04 in the second half of 2025 and a Phase 2 study for its Lyme disease prevention program TP-05 in 2026.</p>\n\n<p>Analysts widely applauded Tarsus' strong performance, reiterating Buy ratings and raising price targets, citing the company's impressive growth trajectory, potential for further market penetration, and robust pipeline opportunities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tarsus Pharmaceuticals Soars 5.74% as Strong 2024 Results Fuel Growth Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-26 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tarsus Pharmaceuticals, Inc. (TARS) stock surged 5.74% in the pre-market session on Wednesday, driven by the company's impressive 2024 financial results and robust growth prospects for its leading product XDEMVY.</p>\n\n<p>The biopharmaceutical company reported stellar full-year 2024 net product sales of $180.1 million for XDEMVY, exceeding expectations and reflecting the successful execution of its commercial strategies. Key highlights included:</p>\n- Expansion of the sales force from 100 to 150 representatives, increasing reach to over 15,000 eye care physicians.\n- Securing commercial and Medicare coverage for XDEMVY, extending to more than 90% of potential patient lives.\n- Compelling data demonstrating XDEMVY's objective benefits in improving measures of Demodex blepharitis (DB) and patient outcomes like fluctuating vision.\n- Successful launch of a direct-to-consumer advertising campaign, driving patient engagement and awareness.\n\n<p>Tarsus also provided promising updates on its pipeline, including plans to initiate a Phase 2 trial for its ocular rosacea treatment TP-04 in the second half of 2025 and a Phase 2 study for its Lyme disease prevention program TP-05 in 2026.</p>\n\n<p>Analysts widely applauded Tarsus' strong performance, reiterating Buy ratings and raising price targets, citing the company's impressive growth trajectory, potential for further market penetration, and robust pipeline opportunities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TARS","symbol_name":"Tarsus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1172093281","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172093281","pubTimestamp":1740580886,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tarsus Pharmaceuticals, Inc.  stock surged 5.74% in the pre-market session on Wednesday, driven by the company's impressive 2024 financial results and robust growth prospects for its leading product XDEMVY.The biopharmaceutical company reported stellar full-year 2024 net product sales of $180.1 million for XDEMVY, exceeding expectations and reflecting the successful execution of its commercial strategies. Key highlights included:. - Expansion of the sales force from 100 to 150 representatives, i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TARS":"Tarsus Pharmaceuticals, Inc."},"translate_title":"2024年强劲业绩推动增长势头，Tarsus Pharmaceuticals股价飙升5.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1},"content_text":"Tarsus Pharmaceuticals, Inc. (TARS) stock surged 5.74% in the pre-market session on Wednesday, driven by the company's impressive 2024 financial results and robust growth prospects for its leading product XDEMVY.\nThe biopharmaceutical company reported stellar full-year 2024 net product sales of $180.1 million for XDEMVY, exceeding expectations and reflecting the successful execution of its commercial strategies. Key highlights included:\n- Expansion of the sales force from 100 to 150 representatives, increasing reach to over 15,000 eye care physicians.\n- Securing commercial and Medicare coverage for XDEMVY, extending to more than 90% of potential patient lives.\n- Compelling data demonstrating XDEMVY's objective benefits in improving measures of Demodex blepharitis (DB) and patient outcomes like fluctuating vision.\n- Successful launch of a direct-to-consumer advertising campaign, driving patient engagement and awareness.\n\nTarsus also provided promising updates on its pipeline, including plans to initiate a Phase 2 trial for its ocular rosacea treatment TP-04 in the second half of 2025 and a Phase 2 study for its Lyme disease prevention program TP-05 in 2026.\nAnalysts widely applauded Tarsus' strong performance, reiterating Buy ratings and raising price targets, citing the company's impressive growth trajectory, potential for further market penetration, and robust pipeline opportunities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}